Sylvie Scharl
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials.
König D, Scharl S, Vuong D, Guckenberger M, Furrer K, Opitz I, Weder W, Rothschild S, Ochsenbein A, Zippelius A, Addeo A, Mark M, Eboulet E, Hayoz S, Thierstein S, Betticher D, Ris H, Stupp R, Curioni-Fontecedro A, Peters S, Pless M, Früh M. Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials. ESMO Open 2022; 7:100455.
Apr 7, 2022Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials.
Apr 7, 2022ESMO Open 2022; 7:100455
König D P, Scharl Sylvie, Vuong D, Guckenberger M, Furrer Katarzyna, Opitz Isabella, Weder W, Rothschild S I, Ochsenbein A, Zippelius A, Addeo Alfredo, Mark M, Eboulet E I, Hayoz S, Thierstein S, Betticher D C, Ris H-B, Stupp R, Curioni-Fontecedro A, Peters S, Pless M, Früh M
Risk Factors for the Development of Fistulae and Stenoses in Crohn Disease Patients in the Swiss Inflammatory Bowel Disease Cohort
Zeitz J, Rogler G, Fried M, Sulz M, Vavricka S, Scharl S, Misselwitz B, Frei P, Biedermann L, Labenz C, Fournier N, Scharl M. Risk Factors for the Development of Fistulae and Stenoses in Crohn Disease Patients in the Swiss Inflammatory Bowel Disease Cohort. Inflamm Intest Dis 2017; 1:172-181.
Feb 25, 2017Risk Factors for the Development of Fistulae and Stenoses in Crohn Disease Patients in the Swiss Inflammatory Bowel Disease Cohort
Feb 25, 2017Inflamm Intest Dis 2017; 1:172-181
Zeitz Jonas, Rogler Gerhard, Fried Michael, Sulz Michael, Vavricka Stephan R, Scharl Sylvie, Misselwitz Benjamin, Frei Pascal, Biedermann Luc, Labenz Christian, Fournier Nicolas, Scharl Michael
Cytomegalovirus disease in inflammatory bowel disease: epidemiology and disease characteristics in a large single-centre experience
Bontà J, Rogler G, Fried M, Scharl S, Vavricka S, Sulz M, Biedermann L, Frei P, Zeitz J, Scharl M. Cytomegalovirus disease in inflammatory bowel disease: epidemiology and disease characteristics in a large single-centre experience. Eur J Gastroenterol Hepatol 2016; 28:1329-34.
Nov 1, 2016Cytomegalovirus disease in inflammatory bowel disease: epidemiology and disease characteristics in a large single-centre experience
Nov 1, 2016Eur J Gastroenterol Hepatol 2016; 28:1329-34
Bontà Jonas, Rogler Gerhard, Fried Michael, Scharl Sylvie, Vavricka Stephan R, Sulz Michael, Biedermann Luc, Frei Pascal, Zeitz Jonas, Scharl Michael
Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort
Spalinger M, Scharl M, Rogler G, Fried M, Vavricka S, Scharl S, Frei P, Sulz M, Rossel J, Biedermann L, Zeitz J. Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort. PloS one 2016; 11:e0160215.
Jul 28, 2016Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort
Jul 28, 2016PloS one 2016; 11:e0160215
Spalinger Marianne R, Scharl Michael, Rogler Gerhard, Fried Michael, Vavricka Stephan R, Scharl Sylvie, Frei Pascal, Sulz Michael, Rossel Jean-Benoit, Biedermann Luc, Zeitz Jonas
Malignancies in Patients with Inflammatory Bowel Disease: A Single-Centre Experience
Madanchi M, Rogler G, Vavricka S, Frei P, Biedermann L, Sulz M, Scharl S, Samaras P, Barthel C, Zeitz J, Scharl M. Malignancies in Patients with Inflammatory Bowel Disease: A Single-Centre Experience. Digestion 2016; 94:1-8.
Jun 18, 2016Malignancies in Patients with Inflammatory Bowel Disease: A Single-Centre Experience
Jun 18, 2016Digestion 2016; 94:1-8
Madanchi Mehdi, Rogler Gerhard, Vavricka Stephan R, Frei Pascal, Biedermann Luc, Sulz Michael, Scharl Sylvie, Samaras Panagiotis, Barthel Christiane, Zeitz Jonas, Scharl Michael
The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease
Vögelin M, Rogler G, Fried M, Sulz M, Zeitz J, Scharl S, Vavricka S, Frei P, Biedermann L, Scharl M. The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease. PloS one 2016; 11:e0155218.
May 23, 2016The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease
May 23, 2016PloS one 2016; 11:e0155218
Vögelin Marius, Rogler Gerhard, Fried Michael, Sulz Michael, Zeitz Jonas, Scharl Sylvie, Vavricka Stephan R, Frei Pascal, Biedermann Luc, Scharl Michael
The Clinical Relevance of the IBD-Associated Variation within the Risk Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 2 in Patients of the Swiss IBD Cohort
Spalinger M, Scharl M, Rogler G, Fried M, Vavricka S, Scharl S, Frei P, Sulz M, Rossel J, Zeitz J, Biedermann L, Voegelin M. The Clinical Relevance of the IBD-Associated Variation within the Risk Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 2 in Patients of the Swiss IBD Cohort. Digestion 2016; 93:182-92.
Feb 27, 2016The Clinical Relevance of the IBD-Associated Variation within the Risk Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 2 in Patients of the Swiss IBD Cohort
Feb 27, 2016Digestion 2016; 93:182-92
Spalinger Marianne R, Scharl Michael, Rogler Gerhard, Fried Michael, Vavricka Stephan R, Scharl Sylvie, Frei Pascal, Sulz Michael, Rossel Jean-Benoit, Zeitz Jonas, Biedermann Luc, Voegelin Marius
Patients' perceptions on the impact of coffee consumption in inflammatory bowel disease: friend or foe?--a patient survey
Barthel C, Rogler G, Wiegand N, Sulz M, Fried M, Vavricka S, Frei P, Scharl M, Scharl S, Wiegand S, Biedermann L. Patients' perceptions on the impact of coffee consumption in inflammatory bowel disease: friend or foe?--a patient survey. Nutr J 2015; 14:78.
Aug 12, 2015Patients' perceptions on the impact of coffee consumption in inflammatory bowel disease: friend or foe?--a patient survey
Aug 12, 2015Nutr J 2015; 14:78
Barthel Christiane, Rogler Gerhard, Wiegand Nico, Sulz Michael, Fried Michael, Vavricka Stephan R, Frei Pascal, Scharl Michael, Scharl Sylvie, Wiegand Sandra, Biedermann Luc